Medi-Cal AWP fraud suit expands
California Attorney General sues 39 pharmaceutical manufacturers for reporting inflated prices to the state's Medi-Cal Medicaid program. The suit, filed Aug. 25 in U.S. District Court in Boston, is an expansion of a 2003 California whistleblower suit against Abbott and Wyeth. Suit adds 38 defendants; Wyeth was dropped from the list of defendants after further investigation, the AG's office said. The defendant includes a variety of manufacturers: including both brand firms (Amgen, GlaxoSmithKline, Bristol-Myers Squibb and Novartis) as well as generic firms (Roxane, Mylan, Sandoz and Teva). Notably absent from the suit are Lilly, Merck, Pfizer and Johnson & Johnson. The suit alleges that the firms defrauded the state by reporting inflated wholesale prices to pricing compendia, which Medi-Cal used to determine physician reimbursement rates. California is one of a number of states suing manufacturers for pricing fraud based on data provided by whistleblowing pharmacy Ven-A-Care (1"The Pink Sheet" Oct. 1, 2001, p. 12)...
You may also be interested in...
Merck, Lilly, Johnson & Johnson and DuPont are examples of manufacturers who do not market the "spread" between average wholesale prices and actual prices, Ven-A-Care President Zachary Bentley told a Congressional hearing on AWPs Sept. 21.
While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year.
The recently US FDA-cleared Velys robotic-assisted system from DePuy Synthes has distinct features. It also has a small footprint that makes it well-suited for ambulatory surgery centers. See what Larry Biegelsen, an analyst with Wells Fargo, said about it here.